Healthcare / Medical Care FacilitiesTokyo
$614.00
-21.00 (-3.31%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $340.5M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.4B
P/E
62.1x
↑EV/EBITDA
6.1x
↓ROE
1.2%
↑Gross Margin
67.9%
↑Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-21.7%
FCF CAGR
-57.5%
FCF margin
8.1%
FCF / Net income
6.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.19B · net income $55.8M · FCF $340.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.19B | $4.19B | $4.17B | $5.41B | $8.74B |
| Net Income | $55.8M | $55.8M | $-309.2M | $518.4M | $2.16B |
| EBITDA | $372.4M | $372.4M | $-65.8M | $1.09B | $3.16B |
| EPS | — | — | -56.55 | 94.59 | 387.21 |
| Gross Margin | 67.9% | 67.9% | 65.7% | 64.7% | 64.0% |
| Operating Margin | 2.3% | 2.3% | -2.9% | 15.4% | 34.1% |
| Net Margin | 1.3% | 1.3% | -7.4% | 9.6% | 24.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | 0.23 | 0.14 | 0.20 |
| Current Ratio | 2.27 | 2.27 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $340.5M | $340.5M | $430.7M | $-284.1M | $4.43B |
| Returns | |||||
| ROE | 1.2% | 1.2% | -6.8% | 11.3% | 49.2% |
| Valuation | |||||
| P/E | 62.08 | 62.08 | — | 9.67 | 4.07 |
| EV/EBITDA | 6.12 | 6.12 | — | 5.05 | 1.51 |
| P/B | 0.73 | 0.73 | 0.82 | 1.89 | 2.00 |
| Growth & Yield | |||||
| Revenue Growth | 0.6% | 0.6% | -23.0% | -38.1% | — |
| EPS Growth | — | — | -159.8% | -75.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-10.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-56.55 → n/d
Residual
-10.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.